BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis

被引:135
作者
Cremolini, C. [1 ]
Di Bartolomeo, M. [2 ]
Amatu, A. [3 ]
Antoniotti, C. [1 ]
Moretto, R. [1 ]
Berenato, R. [2 ]
Perrone, F. [4 ]
Tamborini, E. [4 ]
Aprile, G. [5 ]
Lonardi, S. [6 ]
Sartore-Bianchi, A. [3 ]
Fontanini, G. [7 ]
Milione, M. [4 ]
Lauricella, C. [8 ]
Siena, S. [3 ,8 ]
Falcone, A. [1 ]
de Braud, F. [2 ]
Loupakis, F. [1 ]
Pietrantonio, F. [2 ]
机构
[1] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, I-20133 Milan, Italy
[3] Osped Niguarda Ca Granda, SC Oncol Falck, Niguarda Canc Ctr, Milan, Italy
[4] Fdn IRCCS Ist Nazl Tumori, Dept Pathol & Mol Biol, I-20133 Milan, Italy
[5] Azienda Osped Univ, Dept Med Oncol, Udine, Italy
[6] Ist Oncol Veneto IRCCS, UOC Oncol Med 1, Padua, Italy
[7] Univ Pisa, Div Pathol, Dept Surg, Pisa, Italy
[8] Univ Milan, Milan, Italy
关键词
colorectal cancer; BRAF; codons; 594; and; 596; prognosis; 1ST-LINE TREATMENT; PLUS BEVACIZUMAB; RAS MUTATIONS; ACTIVATION; FOLFOXIRI; CETUXIMAB; THERAPY;
D O I
10.1093/annonc/mdv290
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: While the negative prognostic role of BRAF V600E mutation in metastatic colorectal cancer (mCRC) is well established, the impact of BRAF codons 594 and 596 mutations, occurring in <1% of CRCs, is completely unknown. The present work aims to describe clinical, pathological and molecular features and prognosis of BRAF codons 594 and 596 mutant mCRCs, compared with BRAF V600E mutant and wild-type ones. Patients and methods: Patients treated for mCRC at three Italian Institutions between October 2006 and October 2014, with available KRAS and NRAS codon 12, 13, 59, 61, 117 and 146 and BRAF codon 594, 596 and 600 mutational status, as detected by means of direct sequencing or matrix assisted laser desorption ionization time-of-flight MassArray, were included. Results: Ten patients bearing BRAF codons 594 or 596 mutated tumors were identified and compared with 77 and 542 patients bearing BRAF V600E mutated and BRAF wild-type tumors, respectively. While BRAF V600E mutated tumors were more frequently right-sided, mucinous and with peritoneal spread, BRAF 594 or 596 mutated were more frequently rectal, nonmucinous and with no peritoneal spread. All BRAF 594 or 596 mutated tumors were microsatellite stable. Patients with BRAF codons 594 or 596 mutated tumors had markedly longer overall survival (OS) when compared with BRAF V600E mutated [median OS: 62.0 versus 12.6 months; hazard ratio: 0.36 (95% confidence interval 0.20-0.64), P = 0.002], both at univariate and multivariate analyses. Conclusions: BRAF codon 594 or 596 mutated mCRCs are different from BRAF V600E ones in terms of molecular features, pathological characteristics and clinical outcome. This is consistent with preclinical evidences of a kinase inactivating effect of these mutations. The role of CRAF in transducing the intracellular signal downstream BRAF 594 or 596 mutated proteins opens the way to further preclinical investigation.
引用
收藏
页码:2092 / 2097
页数:6
相关论文
共 25 条
[1]  
[Anonymous], CLIN PRACT GUID ONC
[2]  
[Anonymous], GEN OV BRAF
[3]   Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis [J].
De Roock, Wendy ;
Claes, Bart ;
Bernasconi, David ;
De Schutter, Jef ;
Biesmans, Bart ;
Fountzilas, George ;
Kalogeras, Konstantine T. ;
Kotoula, Vassiliki ;
Papamichael, Demetris ;
Laurent-Puig, Pierre ;
Penault-Llorca, Frederique ;
Rougier, Philippe ;
Vincenzi, Bruno ;
Santini, Daniele ;
Tonini, Giuseppe ;
Cappuzzo, Federico ;
Frattini, Milo ;
Molinari, Francesca ;
Saletti, Piercarlo ;
De Dosso, Sara ;
Martini, Miriam ;
Bardelli, Alberto ;
Siena, Salvatore ;
Sartore-Bianchi, Andrea ;
Tabernero, Josep ;
Macarulla, Teresa ;
Di Fiore, Frederic ;
Gangloff, Alice Oden ;
Ciardiello, Fortunato ;
Pfeiffer, Per ;
Qvortrup, Camilla ;
Hansen, Tine Plato ;
Van Cutsem, Eric ;
Piessevaux, Hubert ;
Lambrechts, Diether ;
Delorenzi, Mauro ;
Tejpar, Sabine .
LANCET ONCOLOGY, 2010, 11 (08) :753-762
[4]   Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer [J].
Di Nicolantonio, Federica ;
Martini, Miriam ;
Molinari, Francesca ;
Sartore-Bianchi, Andrea ;
Arena, Sabrina ;
Saletti, Piercarlo ;
De Dosso, Sara ;
Mazzucchelli, Luca ;
Frattini, Milo ;
Siena, Salvatore ;
Bardelli, Alberto .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (35) :5705-5712
[5]   Panitumumab-FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer [J].
Douillard, Jean-Yves ;
Oliner, Kelly S. ;
Siena, Salvatore ;
Tabernero, Josep ;
Burkes, Ronald ;
Barugel, Mario ;
Humblet, Yves ;
Bodoky, Gyorgy ;
Cunningham, David ;
Jassem, Jacek ;
Rivera, Fernando ;
Kocakova, Ilona ;
Ruff, Paul ;
Blasinska-Morawiec, Maria ;
Smakal, Martin ;
Canon, Jean Luc ;
Rother, Mark ;
Williams, Richard ;
Rong, Alan ;
Wiezorek, Jeffrey ;
Sidhu, Roger ;
Patterson, Scott D. .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (11) :1023-1034
[6]   Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF [J].
Heidorn, Sonja J. ;
Milagre, Carla ;
Whittaker, Steven ;
Nourry, Arnaud ;
Niculescu-Duvas, Ion ;
Dhomen, Nathalie ;
Hussain, Jahan ;
Reis-Filho, Jorge S. ;
Springer, Caroline J. ;
Pritchard, Catrin ;
Marais, Richard .
CELL, 2010, 140 (02) :209-221
[7]   FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial [J].
Heinemann, Volker ;
von Weikersthal, Ludwig Fischer ;
Decker, Thomas ;
Kiani, Alexander ;
Vehling-Kaiser, Ursula ;
Al-Batran, Salah-Eddin ;
Heintges, Tobias ;
Lerchenmueller, Christian ;
Kahl, Christoph ;
Seipelt, Gernot ;
Kullmann, Frank ;
Stauch, Martina ;
Scheithauer, Werner ;
Hielscher, Joerg ;
Scholz, Michael ;
Mueller, Sebastian ;
Link, Hartmut ;
Niederle, Norbert ;
Rost, Andreas ;
Hoeffkes, Heinz-Gert ;
Moehler, Markus ;
Lindig, Reinhard U. ;
Modest, Dominik P. ;
Rossius, Lisa ;
Kirchner, Thomas ;
Jung, Andreas ;
Stintzing, Sebastian .
LANCET ONCOLOGY, 2014, 15 (10) :1065-1075
[8]  
Ikenoue T, 2003, CANCER RES, V63, P8132
[9]   FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer [J].
Loupakis, F. ;
Cremolini, C. ;
Salvatore, L. ;
Masi, G. ;
Sensi, E. ;
Schirripa, M. ;
Michelucci, A. ;
Pfanner, E. ;
Brunetti, I. ;
Lupi, C. ;
Antoniotti, C. ;
Bergamo, F. ;
Lonardi, S. ;
Zagonel, V. ;
Simi, P. ;
Fontanini, G. ;
Falcone, A. .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) :57-63
[10]   Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer [J].
Loupakis, Fotios ;
Cremolini, Chiara ;
Masi, Gianluca ;
Lonardi, Sara ;
Zagonel, Vittorina ;
Salvatore, Lisa ;
Cortesi, Enrico ;
Tomasello, Gianluca ;
Ronzoni, Monica ;
Spadi, Rosella ;
Zaniboni, Alberto ;
Tonini, Giuseppe ;
Buonadonna, Angela ;
Amoroso, Domenico ;
Chiara, Silvana ;
Carlomagno, Chiara ;
Boni, Corrado ;
Allegrini, Giacomo ;
Boni, Luca ;
Falcone, Alfredo .
NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (17) :1609-1618